Know Cancer

forgot password

A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS)

18 Years
Open (Enrolling)
Ductal Carcinoma in Situ

Thank you

Trial Information

A Pilot Study of Chemo-prevention of Green Tea in Women With Ductal Carcinoma in Situ (DCIS)

Many studies have shown that green tea may have anti-cancer and anti-inflammatory effects in
cancer cells and animal models of breast cancer. Some studies have found that Asian women
who drink many cups of green tea have lower rates of breast cancer. Green tea may have an
effect on proliferative and inflammatory pathways. Women with ductal carcinoma in situ
(DCIS) have been found to have inflammation in the breast tissue surrounding DCIS lesions.
Inflammatory pathways are being studied for a possible link to cancer. This study is
designed to evaluate changes in biomarkers of proliferation, inflammation, and angiogenesis
in response to green tea intake.

Inclusion Criteria:

- Histologically confirmed DCIS by breast core biopsy with a corresponding lesion on
breast MRI of at least 1-cm3 in volume.

- Patients may have undergone treatment with prior chemotherapy if this was greater
than 12 months prior to current diagnosis.

- Age >18 years.

- ECOG performance status <2 (Karnofsky >60%)

- Life expectancy of greater than 12 months.

- Normal organ and marrow function as defined below:

- leukocytes >3,000/mcL

- absolute neutrophil count >1,500/mcL

- platelets >100,000/mcL

- total bilirubin within normal institutional limits

- AST(SGOT) & ALT(SGPT)within normal institutional limits

- creatinine <1.5 times institutional upper limit of normal or creatinine clearance >60
mL/min/1.73 m2

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Pregnancy

- Patients who have undergone prior excisional biopsy for DCIS.

- Patients who are unable to undergo MRI due to claustrophobia or other reason.

- Patients with ipsilateral treatment for DCIS or breast cancer within 12 months prior
to entering this study.

- Patients receiving any other chemotherapy or investigational agents.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to green tea extracts or sensitivity to green tea.

- Uncontrolled concurrent illness including, but not limited to: ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Percent change in K167 staining

Outcome Time Frame:

Prior to starting study and after 4-6 weeks of treatment

Safety Issue:


Principal Investigator

Nora Jaskowiak, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Chicago


United States: Food and Drug Administration

Study ID:




Start Date:

February 2010

Completion Date:

December 2013

Related Keywords:

  • Ductal Carcinoma In Situ
  • DCIS
  • Carcinoma
  • Carcinoma in Situ
  • Carcinoma, Intraductal, Noninfiltrating
  • Carcinoma, Ductal, Breast
  • Carcinoma, Ductal



The University of ChicagoChicago, Illinois  60637